echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > JAHA: Sodium-glucose cotransporter 2 inhibitors, all-cause mortality, and cardiovascular outcomes in patients with type 2 diabetes

    JAHA: Sodium-glucose cotransporter 2 inhibitors, all-cause mortality, and cardiovascular outcomes in patients with type 2 diabetes

    • Last Update: 2021-09-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, the heart blood vessels published a research article on the disease areas authoritative magazine JAHA, the study was designed to evaluate the sodium - glucose cotransporter 2 inhibitors in reducing type 2 diabetes efficacy rates of adult mortality and cardiovascular outcomes occur
    .

    Heart vascular diabetes


     
    The researchers conducted a Bayesian meta-analysis of randomized controlled trials comparing sodium-glucose cotransporter 2 inhibitors with placebo, and used meta-regression to assess the association between treatment effects and the incidence of events in the control group
    .

    53 randomized controlled trials were included in the synthetic analysis
    .


    Enpagliflozin, canagliflozin and dapagliflozin reduced all-cause mortality (empagliflozin: ratio [RR] of 0.
    79; 95% confidence interval [CI] of 0.
    63-0.
    97; canagliflozin Net: RR is 0.
    86; 95%CI is 0.


    There is little evidence that Ieggliflozin and Soxaggliflozin can reduce all-cause mortality and cardiovascular mortality compared with placebo
    .


    There was no correlation between the treatment effect of all-cause mortality and cardiovascular mortality and the incidence of events in the control group


    Compared with placebo in stroke , empagliflozin, canagliflozin and dapagliflozin reduced the incidence of all-cause mortality and cardiovascular mortality


    Original source:

    Matthew S.


    Freiberg.
    et al.
    HIV Infection and the Risk of World Health Organization--Defined Sudden Cardiac Death .
    JAHA.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.